for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BioCryst Pharmaceuticals, Inc.

BCRX.OQ

Latest Trade

1.78USD

Change

-0.14(-7.07%)

Volume

113,841

Today's Range

1.77

 - 

1.93

52 Week Range

1.77

 - 

9.94

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.91
Open
1.91
Volume
113,841
3M AVG Volume
30.96
Today's High
1.93
Today's Low
1.77
52 Week High
9.94
52 Week Low
1.77
Shares Out (MIL)
110.44
Market Cap (MIL)
224.19
Forward P/E
-1.63
Dividend (Yield %)
--

Next Event

Q4 2019 BioCryst Pharmaceuticals Inc Earnings Release

Latest Developments

More

Biocryst - On Nov 7 Co, Thomas Staab, II, CFO, Mutually Agreed That Staab Will Step Down

Biocryst Pharmaceuticals Q3 Loss Per Share $0.34

BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology. The Company's drug candidates include RAPIVAB, RAPIACTA, ALPIVAB, PERAMIFLU, Avoralstat, BCX7353, other second generation hereditary angioedema (HAE) compounds, Galidesivir and Forodesine. Its product RAPIVAB contains peramivir. ALPIVAB is an intravenous neuraminidase inhibitor. Galidesivir is a broad-spectrum antiviral (BSAV) research program developed for the treatment of hemorrhagic fever viruses. Forodesine is a Purine Nucleoside Phosphorylase (PNP) inhibitor in development by Mundipharma as a treatment for cancer.

Industry

Biotechnology & Drugs

Contact Info

4505 Emperor Blvd Ste 200

+1.919.8591302

http://www.biocryst.com/

Executive Leadership

Robert A. Ingram

Independent Chairman of the Board

Jon P. Stonehouse

President, Chief Executive Officer, Director

Thomas R. Staab

Senior Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer

Yarlagadda S. Babu

Senior Vice President - Drug Discovery

William P. Sheridan

Senior Vice President, Chief Medical Officer

Key Stats

2.33 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.750

2017

-0.780

2018

-0.980

2019(E)

-1.246
Price To Earnings (TTM)
--
Price To Sales (TTM)
19.46
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
-235.27
Return on Equity (TTM)
-99.38

Latest News

Latest News

BRIEF-Biocryst Pharmaceuticals Q1 Loss Per Share $0.26

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

BRIEF-BioCryst Receives European Medicines Agency Approval For Alpivab For Treatment Of Influenza

* BIOCRYST RECEIVES EUROPEAN MEDICINES AGENCY APPROVAL FOR ALPIVAB™ FOR TREATMENT OF INFLUENZA Source text for Eikon: Further company coverage:

BRIEF-Idera Pharma Files Definitive Proxy Statement Over With Pending Merger With Biocryst

* IDERA PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH BIOCRYST PHARMACEUTICALS

BRIEF-RA Capital Management Opposes BioCryst Pharmaceuticals' Proposed Merger With Idera Pharmaceuticals

* RA CAPITAL MANAGEMENT OPPOSES BIOCRYST PHARMACEUTICALS' PROPOSED MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Pharmaceuticals Files Definitive Proxy Statement Related To Pending Merger With Idera Pharmaceuticals

* BIOCRYST PHARMACEUTICALS FILES DEFINITIVE PROXY STATEMENT IN CONNECTION WITH PENDING MERGER WITH IDERA PHARMACEUTICALS

BRIEF-Biocryst Announces Initiation Of The Phase 3 Apex-2 Trial Of BCX7353 In Patients With Hereditary Angioedema

* BIOCRYST ANNOUNCES INITIATION OF THE PHASE 3 APEX-2 TRIAL OF BCX7353 IN PATIENTS WITH HEREDITARY ANGIOEDEMA

BRIEF-Biocryst Reports Q4 Loss Per Share of $0.20

* BIOCRYST REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Great Point Partners Opposes Biocryst Pharma Proposed Merger With Idera Pharma

* GREAT POINT PARTNERS LLC OPPOSES THE BIOCRYST PHARMACEUTICAL PROPOSED MERGER WITH IDERA PHARMACEUTICALS, INC.

BRIEF-Great Point Reports 7.60 Pct Stake In BioCryst Pharmaceuticals

* GREAT POINT PARTNERS, LLC REPORTS 7.60 PERCENT STAKE IN BIOCRYST PHARMACEUTICALS INC AS OF FEBRUARY 6, 2018 - SEC FILING Source text: (http://bit.ly/2HjJO7H) Further company coverage:

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

BRIEF-Biocryst Advancing Potential Treatment For Rare And Severely Debilitating Fibrodysplasia Ossificans Progressiva

* BIOCRYST ADVANCING POTENTIAL TREATMENT FOR RARE AND SEVERELY DEBILITATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million

* Files for mixed shelf of up to $200 million - SEC filing Source text: (http://bit.ly/2m4wZHE) Further company coverage:

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

BRIEF-Biocryst Pharmaceuticals prices public offering of common stock

* Biocryst Pharmaceuticals prices public offering of common stock

BRIEF-BioCryst Pharmaceuticals announces underwritten public offering​

* BioCryst Pharmaceuticals Inc - offering to sell $80 million of its common stock in an underwritten public offering

BRIEF-Biocryst announces positive results from mid-stage HAE trial

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

BRIEF-Biocryst Pharmaceuticals Q2 loss per share $0.21

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Deerfield Management Co reports 6.81 pct passive stake in Biocryst Pharmaceuticals

* Deerfield Management Company, L.p reports a 6.81 percent passive stake in Biocryst Pharmaceuticals Inc as of may 25- sec filing Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up